Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on pioneering therapies through its proprietary spherical nucleic acid (SNA) technology. The company's robust pipeline targets a range of serious conditions, encompassing neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. By harnessing its innovative SNA technology, Exicure is not only aiming to transform treatment paradigms but also to lead the advancement of RNA-based medicine, strategically positioning itself as a key player within the biopharmaceutical industry.